In a large-scale clinical trial, people taking daraxonrasib lived twice as long as those given standard chemotherapy.
The FDA approved Rasonque, the brand name for Daraxonrasib, for late-stage pancreatic cancer patients who haven't responded ...
Morning Overview on MSN
An experimental pill nearly doubled survival in advanced pancreatic cancer in a major trial
An experimental daily pill roughly doubled median survival for patients with advanced pancreatic cancer in a large late-stage ...
Craig's Cause Pancreatic Cancer Society (CCPCS) is mobilizing Canada's first national, ethics-approved study examining the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results